Snapshot from Jul 19, 2026 at 14:14 UTC. For live data and tracking: View Live
Events / Regulatory / Erasca Securities Fraud Class Action
Regulatory securities class action

Erasca Securities Fraud Class Action

Analysis based on 7 articles · First reported Jul 11, 2026 · Last updated Jul 15, 2026

Sentiment
-30
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The lawsuit may negatively impact Erasca's stock price and investor confidence. The outcome could affect the company's ability to raise capital and advance its drug pipeline.

biotechnology pharmaceutical
Event Summary

Rosen Law Firm reminds investors of the August 10, 2026 lead plaintiff deadline in a securities class action against Erasca The lawsuit alleges that Erasca, along with its CEO and CFO, made false and misleading statements about its lead oncology drug candidate ERAS-0015, comparing it favorably to Revolution Medicines' RMC-6236 without disclosing improper comparisons and exposure to patent and trade secret disputes. Investors who purchased Erasca common stock between January 14, 2025 and April 26, 2026 may be eligible for compensation.

Key Actions
100 Erasca made false statements
80 Rosen Law Firm announced class action lawsuit Erasca
Entities Involved
stock
Erasca
Erasca is the defendant in the securities class action, facing allegations of misleading investors about its drug candidate ERAS-0015. The lawsuit could result in financial penalties and reputational damage.
Importance 100.0 Sentiment -60.0
priv
Rosen Law Firm
Rosen Law Firm is the plaintiff's counsel representing investors in the class action. The firm benefits from increased visibility and potential fees if the case succeeds.
Importance 30.0 Sentiment 10.0
stock
Revolution Medicines
Revolution Medicines is mentioned as the competitor whose drug RMC-6236 was used for comparison. The lawsuit does not directly involve Revolution Medicines, but the allegations may indirectly affect its market position.
Importance 20.0 Sentiment 10.0
per
Lawrence Rosen
Lawrence Rosen is the founding partner of Rosen Law Firm and is listed as a contact for the class action. His role is administrative and not directly impacted by the event.
Importance 10.0 Sentiment 5.0
per
Philip Kim
Philip Kim is an attorney at Rosen Law Firm and a contact for the class action. His role is administrative and not directly impacted by the event.
Importance 10.0 Sentiment 5.0
Relationships
Erasca competitor ↔ Revolution Medicines Erasca is a clinical-stage oncology company that directly competes with Revolution Medicines in developing pan-RAS molec
Rosen Law Firm related ↔ Lawrence Rosen
Rosen Law Firm related ↔ Philip Kim
Lawrence Rosen founding partner ↔ Philip Kim Lawrence Rosen is a founding partner of the Rosen Law Firm, where he directs attorneys including Philip Kim. Together, t
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.